Determination of Orelabrutinib in Human Plasma Using LC-MS/MS.
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000001106
Abstract: BACKGROUND Orelabrutinib is a second-generation Bruton tyrosine kinase inhibitor that improves the management of B-cell malignancies. The objective of this study was to develop and validate an LC-MS/MS method for quantifying orelabrutinib in human plasma.… read more here.
Keywords: human plasma; plasma using; determination orelabrutinib; plasma ... See more keywords
Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.991281
Abstract: The aim of the present study was to establish an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the determination of orelabrutinib in rat plasma using futibatinib as internal standard (IS), and to… read more here.
Keywords: orelabrutinib rat; method determination; determination orelabrutinib; plasma ... See more keywords
Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28031205
Abstract: Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib, zanubrutinib,… read more here.
Keywords: orelabrutinib zanubrutinib; zanubrutinib ibrutinib; ibrutinib; determination orelabrutinib ... See more keywords